Palbociclib Price in India: — Brand, Generic and Monthly Cost

CDSCO-approved generics contain the same active molecule at the same dose. Regulatory approval requires the generic to meet the same pharmaceutical quality standards. There are no clinical trial data specific to individual generic manufacturers — that is normal for generics worldwide and not a clinical reason for concern. Your oncologist can tell you if any specific formulation raises a question for your situation, and their advice should guide the choice.

Some versions of the PMJAY health benefits package and state-level extensions include CDK4/6 inhibitors for HR-positive, HER2-negative breast cancer, but coverage depends on your state, the hospital's empanelment status, and your eligibility category. The only reliable way to confirm is to ask your hospital's PMJAY facilitation desk before starting treatment. Do not assume it is covered, and do not assume it is excluded — both assumptions have cost patients money.

Manufacturer patient assistance programmes can reduce or eliminate the cost of the originator for eligible patients. Eligibility is typically income-based and requires documentation — a prescription, proof of income, and sometimes a letter from your oncologist. Apply early, as approval can take several weeks. Some programmes offer bridging supply while your application is processed. Ask your oncologist's coordinator or the hospital social worker to help you prepare the paperwork and submit it correctly.

Palbociclib is sold by multiple manufacturers at different price points, and hospital pharmacies, retail pharmacies, and registered online pharmacies each have different margins and procurement arrangements. The ranges on this page are indicative as of mid-2026. The price you are quoted for a specific product at a specific pharmacy may be higher or lower, and prices can change between cycles — always confirm before each purchase rather than assuming it will be the same as last time.

Coverage varies significantly. Group health policies offered through employers sometimes include oral targeted cancer therapies; many individual and family-floater policies exclude them or place a cap on the oncology benefit. Ask your insurer three specific questions: does the policy cover oral targeted therapy, is palbociclib listed or excluded by name, and what is the annual oncology benefit limit? Get the answer in writing before your first cycle, and keep any pre-authorisation reference number on file.

Tell your oncologist directly that cost is a barrier — this is a clinical conversation, not an administrative one. Your oncologist may recommend a CDSCO-approved generic at a lower price point or connect you with a hospital-based social welfare fund. Some non-governmental organisations also provide financial support to cancer patients in Telangana and Andhra Pradesh; your hospital social worker will know which ones are active in your region and how to apply for support.